Business Wire·Oct 16, 2026, 4:15 PM ET

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock granted inducement equity awards totaling 61,020 shares to seven newly hired employees.
The awards consist of 17,461 inducement stock options & 43,559 inducement restricted stock units.
Awards are governed by the Company's 2022 Inducement Equity Plan, utilized exclusively for new hires or returning employees after a bona fide non-employment period.
Inducement stock options have an exercise price of $41.94, matching the closing stock price on October 12, 2026.
Stock option vesting occurs at 25% on the first anniversary of the start date, with the remaining 75% vesting in 12 equal quarterly installments.
Restricted stock unit vesting occurs in four equal annual installments, contingent on continued service.
Scholar Rock commercializes ISEMBLYD (apitegromab-mstn) in the U.S. for SMA patients aged 2+ receiving SMN2-targeted treatment following FDA approval in September 2026.
The company plans to expand global access to ISEMBLYD in up to 50 countries.
Scholar Rock operates as a global leader in myostatin biology, developing novel monoclonal antibodies to modulate protein growth factors.